Tepotinib shows strong response in lung cancer subgroups during long-term follow-up

Tepotinib's robust and durable activity in a Phase 2 vision study with a median follow-up of 26.1 months reported long-term results for VISION, based on data from November 2022. This is a single-arm phase 2 trial of tepmetko (Tepmetko, Merck/EMD Serono) in patients with advanced non-small cell lung cancer with tissue and/or liquid biopsy-confirmed MET exon 14 skipping. Patients in the study were either treatment-naïve or had received up to two prior treatments.

The researchers found that among 313 patients with an average age of 72 years, the average duration of treatment with tepotinib was 11.5 months and the average follow-up time was 32.6 months. Among the 164 patients who received tepotinib as first-line therapy, the average duration of treatment was 12.4 months. In this patient population, the objective response rate was 57.3% (95% CI, 49.4-65), the median duration of response was 46.4 months (13.8 to not estimable), the median PFS was 12.6 months (9.7-17.7), and the median overall survival (OS) was 21.3 months (14.2-25.9).

OR R was 58.6% (48.8-67.8), median duration of response was 46.4 months (15.2 to not estimable), median PFS was 15.9 months (11-49.7), and median OS was 29.7 months (18.8 to not estimable). Among 149 patients who received second-line or second-line treatment with tepotinib for an average of 10.5 months, the ORR was 45% (36.8053.3) and the median duration of response was 12.6 months (9.5-18.5).

Among all 313 patients, the ORR was 51.4% (45.8-57.1), the median duration of response was 18 months (12.4-46.4), the median PFS was 11.2 months (9.5-13.8), and the median OS was 19.6 months (16.22-22.9). The researchers noted that no new security issues were discovered.

In the long-term follow-up of the largest clinical trial to date targeting MET exon 14 skipping, the VISION study, tepotinibIt continues to show strong and durable activity across different treatment lines, with time-dependent endpoints occurring longest in first-line or first-line treatment in patients with tissue biopsy-detected MET exon 14 skipping. Tepotinib demonstrated a manageable safety profile, consistent with observations of earlier known safety signals.